Fluoroquinolone-based antibacterial chemoprophylaxis administered in situations in which the prevalence of fluoroquinolone-resistant Escherichia coli is low (<3% to 5%) can reliably reduce the risk for invasive gram-negative bacillary infection, and, if supplemented by grampositive agents such as rifampin, penicillin, or macrolides, can reduce the risk of developing invasive infections caused by gram-positive microorganisms, including Viridans streptococci and coagulase-negative staphylococci. In the published literature, fluoroquinolone-based chemoprophylaxis does not reliably reduce the incidence of febrile neutropenic episodes, neutropenic episode-related mortality, or physician-initiated systemic antimicrobial prescribing behavior. Prophylaxis should only be prescribed in defined patient populations from the first day of cytotoxic therapy until neutrophil regeneration in environments in which the prevalence of gram-negative bacillary resistance to the prophylaxis strategy is low. Small phase II clinical trials suggest that empirical antibacterial therapy of unexplained fevers in neutropenic patients receiving effective fluoroquinolone-based prophylaxis under defined epidemiologic circumstances may be safely discontinued early. Better discriminators of infection in febrile neutropenic patients are needed. (JNCCN 2004;2:433-444) It has been 38 years since the relationship between the absolute circulating neutrophil count (ANC), fever, and infection was first described.
It has been 38 years since the relationship between the absolute circulating neutrophil count (ANC), fever, and infection was first described. 1 The accepted definition of neutropenia is an ANC below 0.5 ϫ 10 9 /L or an ANC less than 1.0 ϫ 10 9 /L with a predicted decline to below 0.5 ϫ 10 9 /L within 48 hours. [2] [3] [4] [5] Early studies indicated that the majority of infections seen in neutropenic patients were caused by bacteria that colonize integumental surfaces. 6, 7 More recent studies have implicated cytotoxic regimen-induced intestinal mucosal damage as an important component in the trans locational pathogenesis of these infections. [8] [9] [10] [11] [12] During the late 1960s, the most common etiology of infection in neutropenic cancer patients was Staphylococcus aureus, and until the introduction of methicillin, it was a major cause of death. 13 Thereafter, aerobic gram-negative bacilli emerged as the most common causes of excess infectious morbidity and mortality in neutropenic cancer patients until the introduction of extended spectrum anti-pseudomonal carboxy penicillin, carbenicillin, used in combination with aminoglycosides such as gentamicin.
14 Over the past decade, gram-positive organisms, particularly the coagulase-negative staphylococci and the viridans group streptococci, have re-emerged as the predominant pathogens.
neutropenic episodes have resulted in lengthened hospital stays by more than a week, at an estimated incremental cost of $3,200 (U.S.) per patient, as well as significant increases in the crude case to fatality rate. 19 For these reasons, it seems prudent to engage strategies by which this excess morbidity and mortality caused by infection can be prevented without negatively impacting on the efficacy of the treatment for the underlying malignancy.
these, coagulase-negative staphylococci accounted for 17.5%; Escherichia coli for 16.3%; viridans group streptococci for 12.7% (with S. mitis being the most common in 50 of 178 isolates); Klebsiella species or Enterobacter species for 12.7%; Staphylococcus aureus for 8.9%; Enterococcus species for 7.3%; and Pseudomonas aeruginosa for 5.5%. 24 
Background of Antibacterial Chemoprophylaxis
Effective antibacterial chemoprophylaxis should reduce the incidence of febrile episodes, reduce the incidence of gram-negative and gram-positive infections, reduce febrile episode-related mortality, be tolerable, and be able to modify physician antibiotic prescribing behavior. Microorganisms that should be targeted include those cited previously. 24 Secondary outcomes include hospitalization, systemic antibiotic administration, strategy-related toxicities, and emergence of resistance.
The clinical circumstances targeted for antibacterial chemoprophylaxis include those in which the administration of intensive cytotoxic therapy would be expected to produce severe, prolonged hematopoietic suppression wherein the ANC is less than 0.5 ϫ 10 9 /L for longer than 7 to 10 days and the absolute lymphocyte count (ALC) is less than 0.7 ϫ 10 9 /L, 25 and to produce severe grade 3 or 4 (National Cancer Institute Common Toxicity Criteria version 2.0, April 30, 1999; available at: http://www.cancer.gov) oropharyngeal and intestinal mucositis. 12 Such patients can include those undergoing remission-induction, re-induction, or consolidation for acute leukemia, those undergoing myeloablative and immunoablative conditioning therapy for hematopoietic stem cell transplantation, and those with gastrointestinal graft-versus-host disease.
Clinical trials of antibacterial chemoprophylaxis may be divided into those focused on nonabsorbable antibiotic combinations consisting of agents such as neomycin, gentamicin, tobramycin, vancomycin, polymyxin B, colistin, and oral nystatin or amphotericin B; absorbable agents including tetracycline, trimethoprim/sulfamethoxazole (TMP/SMX), and the fluoroquinolones (including nalidixic acid, norfloxacin, ciprofloxacin, ofloxacin, enoxacin, pefloxacin, and levofloxacin) with or without additional agents such as metronidazole, penicillin, rifampin, or a macrolide; and parenteral regimens such as the glycopeptide antibiotics.
Oral nonabsorbable antimicrobial regimens have not been consistently effective for reducing the incidence of febrile neutropenic episodes, documented superficial or invasive infection, or overall mortality. In addition, they are unpalatable and costly. Conversely, oral absorbable antibacterial regimens have proved useful, although investigators have cautioned that efficacy appears to be intimately linked with compliance, 26 personal hygiene, the spectrum of antimicrobial activity of the regimen, 27 the cytotoxic potential of the antineoplastic regimen, and the timing of the administration of the regimen relative to the onset of the neutropenia-related risk for bacterial infection. 28, 29 Quinolone-based prophylaxis requires a median of approximately 5 days for the suppression of potentially pathogenic aerobic gram-negative bacilli from the bowel. 27 Early studies of systemically absorbable agents such as TMP/SMX were reviewed in the first iteration of the Infectious Diseases Society Fever and Neutropenia Panel. 30 These studies showed that TMP/SMX could reduce infection rates compared with placebo controls among patients with prolonged neutropenia. The enthusiasm for this strategy was dampened by the lack of effect of TMP/SMX prophylaxis on systemic antibacterial use overall, on P. aeruginosa, or on overall mortality; potential augmentation of myelosuppression; and the rising prevalence of gram-negative bacillary resistance.
Fluoroquinolone-Based Antibacterial Chemoprophylaxis
Much of the focus for antibacterial chemoprophylaxis has been on the use of oral fluoroquinolone agents. The experience with oral fluoroquinolones has shown a significant reduction in the morbidity and mortality caused by infection by aerobic gram-negative bacilli compared with TMP/SMX. 28, 31 The tradeoff for this appears to be an increase in the risk of infection caused by gram-positive organisms such as coagulase-negative staphylococci, Enterococcus species, and viridans group streptococci.
The presence of a tunneled indwelling central venous catheter adds to the risk for infections caused by coagulase-negative staphylococci, 32 whereas severe mucositis and periodontal disease appear to predispose to viridans streptococcal infection. 8, [33] [34] [35] A syndrome of viridans streptococcal bacteremia has been recognized among high-dose cytarabine or hematopoietic stem cell transplant recipients that is often associated with pulmonary infiltrates and hypotension. 8, 36, 37 The pathogenesis is believed to involve severe cytotoxic therapy-induced intestinal mucosal damage in the setting of severe prolonged neutropenia and gastrointestinal luminal colonization by these organisms. Oral fluoroquinolone use tends to select for these microorganisms. 38 Of clinical importance is the inconsistent susceptibility of these organisms to penicillin G and the apparent need to modify the empirical antibacterial regimen by adding intravenous vancomycin to improve the likelihood of a successful outcome for the febrile neutropenic episode. Bacterial infections among TMP/SMX recipients have been caused by coagulasenegative staphylococci, viridans streptococci, and TMP/SMX-resistant aerobic gram-negative bacilli such as P. aeruginosa.
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Four meta-analyses have been published examining the role of fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients, [39] [40] [41] [42] the results of which are summarized in Table 1 . Each of these publications includes multiple meta-analyses.
Cruciani et al. 39 reported two meta-analyses, each examining four outcomes: gram-negative bacteremias, gram-positive bacteremias, the incidence of febrile events, and infection-related mortality. The first examined 13 trials comprising 1,155 randomized subjects and comparing fluoroquinolones with TMP/SMX, nonabsorbable antimicrobials, or placebo, and the second examined the efficacy of fluoroquinolones plus additional agents that augmented coverage for grampositive microorganisms. 39 In the first analysis, a significant reduction in gram-negative bacteremias was found among fluoroquinolone recipients compared with controls receiving TMP/SMX, nonabsorbable antibiotics, or placebo. However, no treatment effect was found on the incidence of gram-positive bacteremia, febrile events, or infection-related mortality.
In the second analysis, six trials predictably showed no treatment effect with respect to the incidence of gram-negative bacteremia, but rather a significant reduction in the incidence of gram-positive bacteremia as a function of the added gram-positive agents in the prophylaxis regimen. This effect was also seen in a sensitivity analysis that excluded studies in which nonabsorbable antibiotics were given in the control groups. No effect was seen on incidence of fever (73% and 76% in the study and control groups, respectively) or on infection-related mortality (4.6% and 5.6% in the study and control groups, respectively). 39 Despite the pooling of data, the infection-related mortality rates in these studies were so low that the power of the analysis to show a difference-even if one existedwas low.
This group also performed a follow-up analysis of the effect of augmenting fluoroquinolone prophylaxis with gram-positive prophylaxis in nine randomized controlled clinical trials encompassing 1,202 randomized subjects. 42 This analysis evaluated nine outcomes, including total number of bloodstream infections, gram-negative infections, staphylococcal infections, streptococcal infections, clinically documented infections, unexplained fevers, incidence of febrile neutropenic events, overall mortality, and adverse treatment effects. The analyses showed significant reductions in the incidences of total number of bloodstream infections, staphylococcal infections, streptococcal infections, and the incidence of febrile neutropenic events. The number of treatment-related side effect was higher among patients receiving the fluoroquinolone plus gram-positive prophylaxis. As might be expected from the study design, no treatment effect was found on the incidence of gramnegative infections.
Rotstein et al. 40 reported on four meta-analyses, each on six different outcomes. Outcomes included: gram-negative infections, gram-positive infections, fungal superinfection, incidence of febrile episodes, overall mortality, and treatment-related side effects. The first meta-analysis compared fluoroquinolones to placebo in five trials with 394 randomized subjects, the second compared fluoroquinolones with other oral antibacterial agents (vancomycin + polymyxin, TMP/SMX + colistin, TMP/SMX, gentamicin, vancomycin plus tobramycin + colistin, vancomycin + gentamicin + colistin, vancomycin + neomycin plus nalidixic acid, polymyxin + nystatin, and polymyxin) in 16 trials with 1,362 randomized subjects, the third compared ciprofloxacin with other fluoroquinolones in three trials with 902 randomized subjects, and the fourth compared fluoroquinolones plus additional gram-positive coverage (vancomycin, penicillin G, penicillin V, amoxicillin, rifampin, or roxithromycin) to a fluoroquinolone alone in six trials with 922 subjects. 40 The first analysis (fluoroquinolones vs. placebo) showed significant reductions in the incidence of gram-negative infections and febrile neutropenic events, but no treatment effect on gram-positive infections (similar to the results of Cruciani et al. 39 ), fungal superinfection, or mortality. The treatmentrelated side effects were more frequent among fluoroquinolone recipients compared with control subjects. The second analysis (comparing fluoroquinolones with other oral prophylaxis regimens) showed a reduction in gram-negative infections, but no effects on gram-positive infections, fungal superinfections, febrile morbidity, or mortality. Fewer treatment-related side effects were seen among fluoroquinolone recipients compared with the control subjects. The third analysis (comparing ciprofloxacin with other fluoroquinolones) showed a protective effect among ciprofloxacin recipients against gramnegative infections and a reduction in the incidence of febrile events. The fourth analysis (examining the potential advantage of additional gram-positive prophylaxis), showed a significant reduction in the incidence of gram-positive infections. No other outcome was affected. This was again very similar to the observations in the Italian study. 39 Lastly, Engels et al. 41 reported two meta-analyses. The first included nine trials with 731 randomized subjects and compared fluoroquinolones with placebo or non-treatment. The second included nine trials with 677 randomized subjects comparing fluoroquinolones with TMP/SMX. Each analysis examined 10 outcomes, including gram-negative infections and bacteremia, gram-positive infections and bacteremia, fungal superinfection, microbiologically documented infections, clinically documented infections, total infections, fever episodes, and mortality. Reductions in the incidence of gram-negative infections overall, gram-negative bacteremia, microbiologically documented infections overall, total infections, and the incidence of febrile events were shown. The reductions in microbiologically documented infections and total infections were a function of the treatment effect on gram-negative infections. No treatment effects were seen on gram-positive infections (bacteremia or non-bacteremic), fungal superinfection, clinically documented infections, or overall mortality. The effect on the incidence of febrile events is similar to that reported by Rotstein et al. 40 The second comparison against TMP/SMX showed similar results to the first meta-analysis, except that the fluoroquinolone had no impact on the incidence of fever compared with TMP/SMX. Fluoroquinolones, however, were superior to TMP/SMX with respect to protecting patients against gram-negative infections (bacteremic and non-bacteremic), observations that were shared by other investigators. 39, 40 These systematic reviews could detect prophylactic treatment effects for the fluoroquinolones in a spectrum of outcomes including microbiologically documented infection overall, gram-negative infections overall, and gram-negative bacteremia regardless of whether the controls were placebo, no treatment, or TMP/SMX. Infection-related mortality and overall mortality were not affected by fluoroquinolone prophylaxis in any analysis. Reduction in the incidence of febrile episodes was shown only in the placebo-controlled trials (Table 1) 40,41 ; however, this effect was seen only among non-blinded trials and not in blinded trials, 41 
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Can Fluoroquinolone Antibacterial Chemoprophylaxis Influence Physician Prescribing Behavior for Febrile Neutropenic Patients?
The potential for fluoroquinolone prophylaxis to permit a change in the standard approach to the febrile neutropenic patient is linked to the effectiveness of these agents in the elimination of fever and the risk for infection caused by aerobic gram-negative bacilli. Many investigators would accept that not all fevers in neutropenic patients represent infection and that fever alone is a poor outcome for clinical trials of antibacterial prophylaxis in this patient population. Better discriminators for infection are needed before the kinds of strategies suggested by these trials can enter the domain of standard practice. 47 The observed prophylaxis-related decrease in documented infections has been offset by an increase in unexplained fevers 45 and may be a function of translocation of pyrogenic endotoxins across a cytotoxic therapy-induced damaged intestinal epithelium. 48 Although this is speculation, it is possible that some febrile neutropenic episodes do not require continued antibacterial therapy. A few clinical observations support this hypothesis. Under defined conditions, fluoroquinolone-based antibacterial chemoprophylaxis has influenced physician prescribing behavior in febrile neutropenic episodes. [49] [50] [51] A historical control study from Duke University among autologous hematopoietic transplant recipients treated with ciprofloxacin plus rifampin prophylaxis showed an elimination of febrile neutropenic episodes because of aerobic gram-negative bacillemic infection and that empirical therapy based upon once daily vancomycin plus an aminoglycoside was safe and effective. 50 Furthermore, the use of this prophylaxis regimen reduced the need for empirical antifungal therapy from 33% to 14% as a result of fewer persistent fevers.
A study from the University of Manitoba, Canada, showed that patients developing febrile neutropenic episodes while receiving ciprofloxacin prophylaxis during remission-induction therapy for acute myeloid leukemia could be treated safely and effectively with vancomycin plus ceftazidime-based strategy, wherein the ceftazidime was discontinued before the patient defervesced provided the serial rectal surveillance cultures and 24-to 36-hour blood cultures revealed no evidence of aerobic gram-negative bacilli. 51 In both of these studies, the oral ciprofloxacin prophylaxis regimen was continued throughout the treatment for the febrile neutropenic episode. A third study from Europe showed that empirical systemic antibacterial therapy for febrile neutropenic episodes could be safely discontinued after 72 to 96 hours if the initial workup failed to provide evidence for clinically or microbiologically documented infection and if prophylaxis was continued. 49 The median duration of systemic antibacterial therapy for patients without confirmed infection was 3 days, and the episode-related survival was 100%.
Patients classified after appropriate investigations as having unexplained fevers may have a different natural history than those classified as having documented infections. Indeed, clinical trials of empirical antibacterial therapy in this population have shown higher response rates for unexplained fevers than for documented infections. The observations of these studies are provocative and suggest that unexplained fevers occurring under the circumstances of effective antibacterial prophylaxis may be treated differently than other febrile neutropenic episodes. This would have significant implications with respect to costs of treating these episodes and treatment-related morbidities. This hypothesis should be tested further with well-designed randomized-controlled trials.
What is the Impact of Rising Fluoroquinolone Resistance on the Efficacy of Chemoprophylaxis?
Reports of fluoroquinolone resistance among aerobic gram-negative bacilli associated with bloodstream infections in neutropenic cancer patients began to emerge in the early 1990s. [52] [53] [54] The incidence of fluoroquinolone-resistant E. coli (FREC) bacteremia among patients treated on the EORTC-IATCG clinical trials from 1983 to 1993 increased from zero during the period from 1983 to 1990 to 28% during the period from 1991 to 1993. 52 Of note, the incidence of resistance among strains of P. aeruginosa and Klebsiella pneumoniae remained largely unchanged, at less than 10%. 52 This has been more of a problem among cancer patients treated in institutions with high prevalence rates for gram-negative bacillary fluoroquinolone resistance of over 10% despite community-related resistance prevalences of less than 1%. 55 In 1995, Carratala et al. 54 reported a 37% incidence of fluoroquinolone resistance in 35 of 230 neutropenic cancer patients previously treated with norfloxacin. In an environment with a high (15%) prevalence of fluoroquinolone resistance among gram-negative bacilli, cancer patients receiving ciprofloxacin antibacterial chemoprophylaxis while undergoing high-dose chemotherapy with stem cell rescue experienced colonization with FREC in one third of cases. 56 In another study, from the University of Barcelona, the incidence of ciprofloxacin-resistant E. coli bacteremia in patients undergoing chemotherapy for acute leukemia was higher for those receiving ciprofloxacin prophylaxis (16%) compared with those not receiving (1.9%) ciprofloxacin prophylaxis. 57 There is a significant correlation between the incidence of ciprofloxacin-resistant E. coli bloodstream infection and the increased community and hospital use of fluoroquinolones (r = 0.974, P = 0.005 and r = 0.975, P = 0.005, respectively). 58 Overuse and inappropriate prescribing of fluoroquinolones in the community and in the hospital is strongly linked to resistance and, ultimately, the reduced efficacy of this class of agents for neutropenic cancer patients. It is therefore incumbent on prescription writers of prophylactic antibacterial therapy to have some understanding of the prevalence of gram-negative bacillary resistance in the institution in which they practice and the community from which their patients are derived.
Conclusions
Both "pro" and "con" arguments exist for the use of fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients. These arguments are summarized in Table 2 in consideration of the evidence gleaned in the systematic reviews [39] [40] [41] [42] based on the published clinical trials. When administered in an environment in which the prevalence of fluoroquinolone-resistant E. coli is low (<3%-5%), this strategy reliably reduces the risk for invasive gram-negative bacillary infection, and, if supplemented with additional agents such as rifampin, penicillin, or macrolides antibiotics, the risk for gram-positive infections, including those caused by the viridans streptococci and coagulase-negative staphylococci. Although some trials showed a reduction in the incidence of febrile neutropenic episodes overall, this treatment effect has not been consistent between trials. Furthermore, neither overall mortality nor neutropenic episode-related mortality has been affected by prophylaxis strategies.
Small, single-institution clinical trials have suggested that effective prophylaxis can reduce the risk for invasive gram-negative bacillary infection sufficient to permit discontinuation of gram-negative antibacterial therapy while continuing gram-positive therapy and the prophylaxis regimen. However, the safety and efficacy of strategy has yet to be confirmed by large, multicenter randomized, controlled clinical trials. Similarly, no reduction in the incidence of clinically documented infections has been shown. Proof for the argument that prophylaxis masks the detection of microbiologically documented infections by converting documented infections into unexplained fevers is wanting. In contrast, researchers argue that because the response rates for standard extendedspectrum ␤-lactam plus aminoglycoside combination regimens for empirical therapy of unexplained fevers is higher than that for documented infection (55% vs. 47%; odds ratio, 1.35; 95% CI, 1.22 to 1.49), this "selection" may be an advantage. The 30-day mortality rates for gram-negative bacteremias such as P. aeruginosa in hospitalized cancer patients are high Abbreviations and symbols: ↓, incidence is reduced; ↑, incidence is increased; NSD, no significant difference; FRGNB, fluoroquinolone-resistant gram-negative bacilli.
and approach 20% to 30%. 24, 81 Accordingly, strategies such as fluoroquinolone chemoprophylaxis that can reliably reduce the likelihood of acquiring such infections seem prudent in patients at high risk for serious medical complications. 82, 83 The gram-negative infection-related mortality rate is an outcome not reported in the published trials of fluoroquinolone prophylaxis; accordingly, the question of whether this outcome is affected by prophylaxis cannot be addressed from the available literature. Some trials have reported that prophylaxis permits overgrowth by resistant microorganisms such as yeasts and fluoroquinolone-resistant gram-negative bacilli; however, increased invasive fungal infections have not been seen in the former case, and selection for fluoroquinolone-resistant gramnegative bacilli is most likely in high prevalence environments.
That mortality-related outcomes have not been affected by prophylaxis is probably a function of the effectiveness of "salvage" antibacterial regimens, thus arguing that mortality represents an insensitive endpoint for prophylaxis trials and should be rejected as an argument against use of fluoroquinolone prophylaxis. Therefore, fluoroquinolone-based chemoprophylaxis may be recommended with the intent of reducing the risk for invasive gram-negative infections when prescribed in defined patient populations from the first day of cytotoxic therapy until neutrophil regeneration in environments where the prevalence of gram-negative bacillary resistance to the prophylaxis strategy is low.
